Raymond James Financial
LUCD icon

Raymond James Financial’s Lucid Diagnostics LUCD Stock Holding History

Raymond James Financial’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$604K Buy
+524,936
New +$668K ﹤0.01% 4223
2025
Q3 		– Sell
-791
Closed -$910 – 5969
2025
Q2 		$910 Buy
+791
New +$1.02K ﹤0.01% 6583

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Raymond James Financial's LUCD Position: Q1 2026 in Review

Raymond James Financial opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 524,936 shares worth $604K. The stake represents ﹤0.01% of the portfolio and ranks #4223 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in LUCD as recently as Q2 2025.

Raymond James Financial first reported a position in LUCD in Q2 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Raymond James Financial held 524,936 shares of Lucid Diagnostics worth $604K as of Q1 2026.
  • Lucid Diagnostics was a new Raymond James Financial position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4223 holding.
  • Raymond James Financial first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.